Activation of the JAK-STAT signaling pathway inhibits cytotoxic T lymphocytes and counteracts the antitumor effects of anti-PD-1 immunotherapy in pancreatic cancer (60). Here, PDCD1 is linked to familial pancreatic carcinoma.